Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ARRY

ARRY - Array BioPharma Inc Stock Price, Fair Value and News

$11.68+0.26 (+2.28%)
Market Closed

73/100

ARRY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

73/100

ARRY

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$15.34

Target 3M

$11.57

Target 6M

$12.71

ARRY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARRY Price Action

Last 7 days

14.3%

Last 30 days

17.3%

Last 90 days

39.2%

Trailing 12 Months

74.9%

ARRY RSI Chart

ARRY Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ARRY Valuation

Market Cap

1.8B

Price/Earnings (Trailing)

-53.43

Price/Sales (Trailing)

1.34

EV/EBITDA

10.7K

Price/Free Cashflow

17.92

ARRY Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$15.34

Target 3M

$11.57

Target 6M

$12.71

ARRY Fundamentals

ARRY Revenue

Revenue (TTM)

1.3B

Rev. Growth (Yr)

70.04%

Rev. Growth (Qtr)

8.63%

ARRY Earnings

Earnings (TTM)

-33.4M

Earnings Growth (Yr)

123.7%

Earnings Growth (Qtr)

-22.56%

ARRY Profitability

Operating Margin

26.82%

EBT Margin

-1.98%

Return on Equity

71.48%

Return on Assets

-2.07%

Free Cashflow Yield

5.58%

ARRY Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

-0.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20251.1B1.2B1.3B0
20241.4B1.1B982.2M915.8M
20231.7B1.8B1.6B1.6B
2022905.7M1.1B1.5B1.6B
2021683.2M764.8M814.0M853.3M
2020704.1M760.3M816.5M872.7M
201900469.3M647.9M
2018000290.8M
Get all data in R, Python etc through our Historical Stock Data APIs

About Array BioPharma Inc

ARRY
Array Technologies, Inc. manufactures and sells ground-mounting tracking systems used in solar energy projects in the United States, Spain, Brazil, Australia, and internationally. The company operates in two segments, Array Legacy Operations and STI Operations. Its products include DuraTrack HZ v3, a single axis tracker; Array STI H250 to deliver a lower levelized cost of energy with tracker system; Array OmniTrack; and SmarTrack, a software product that uses site-specific historical weather and energy production data in combination with machine learning algorithms to identify the optimal position for a solar array in real time to enhance its energy production. The company was founded in 1989 and is headquartered in Albuquerque, New Mexico.
 CEO
 WEBSITEhttps://arraytechinc.com
 SECTORTechnology
 INDUSTRYSolar
 EMPLOYEES1096

Array BioPharma Inc Frequently Asked Questions

ARRY is the stock ticker symbol of Array BioPharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Array BioPharma Inc is 1.78 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ARRY's fair value in chart for subscribers.

The fair value guage provides a quick view whether ARRY is over valued or under valued. Whether Array BioPharma Inc is cheap or expensive depends on the assumptions which impact Array BioPharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ARRY.

As of Wed Jan 28 2026, ARRY's PE ratio (Price to Earnings) is -53.43 and Price to Sales (PS) ratio is 1.34. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ARRY PE ratio will change depending on the future growth rate expectations of investors.